Analysis of United States Patent 10,220,076 for Antibody Therapeutics

This report provides a comprehensive analysis of United States Patent 10,220,076, focusing on its core claims, the underlying antibody technology, and the broader patent landscape. The patent, titled "Antibodies to CD37," claims specific antibodies and their use in treating B-cell malignancies. Analysis of prior art and ongoing litigation is crucial for assessing the validity and commercial viability of this patent.

What Are the Core Claims of US Patent 10,220,076?

United States Patent 10,220,076, granted on March 5, 2019, to Sorrento Electronics, Inc., focuses on novel antibodies targeting the CD37 antigen. The claims broadly cover:

Specific Antibody Sequences: Claims 1-14 define specific DNA sequences encoding antibody heavy and light chains, and the corresponding amino acid sequences of these antibodies. These antibodies are designated as "CD37-Specific Antibodies."
Antibody Constructs: Claims 15-25 encompass antibody-drug conjugates (ADCs) and bispecific antibodies incorporating the defined CD37-Specific Antibodies. These constructs are designed for targeted delivery of cytotoxic agents or for engaging immune effector cells.
Pharmaceutical Compositions: Claims 26-31 cover pharmaceutical compositions comprising the CD37-Specific Antibodies or their constructs, along with pharmaceutically acceptable carriers.
Methods of Treatment: Claims 32-48 describe methods of treating various B-cell malignancies, including but not limited to chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), by administering the claimed antibodies or compositions.

The patent’s claims are broad enough to encompass both naked antibodies and antibody conjugates designed for therapeutic intervention.

What is the Underlying Antibody Technology and its Therapeutic Target?

The patent centers on antibodies that bind to CD37, a transmembrane glycoprotein expressed on the surface of normal and malignant B-cells [1]. CD37 is a member of the tetraspanin superfamily and plays a role in B-cell development and activation. Its expression is largely restricted to hematopoietic cells, with high levels found on B-lymphocytes, including cancerous B-cells [2].

The therapeutic rationale for targeting CD37 with antibodies stems from several mechanisms:

Direct Cytotoxicity: Naked antibodies can mediate cell killing through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [3].
Targeted Drug Delivery: By conjugating cytotoxic payloads to CD37-targeting antibodies, ADCs can deliver potent anti-cancer drugs directly to malignant B-cells, minimizing systemic toxicity [4].
Immune Engagement: Bispecific antibodies can be engineered to bind to CD37 on cancer cells and to immune effector molecules, such as T-cell receptors or Fc receptors, thereby recruiting the immune system to eliminate tumor cells [5].

The antibodies claimed in US Patent 10,220,076 are characterized by specific amino acid sequences for their variable regions, which are responsible for antigen binding. These sequences dictate the antibody's affinity and specificity for CD37. The patent provides detailed sequence information for these critical components.

What is the Prior Art Landscape for CD37-Targeting Antibodies?

The development of CD37-targeting antibodies is a competitive field. Several antibodies and approaches have been disclosed and patented prior to the filing of US Patent 10,220,076. Key aspects of the prior art include:

Early Generation Antibodies: Research dating back to the late 1990s identified antibodies that bind to CD37. For example, the antibody BDG-19 was described in scientific literature for its ability to bind CD37 and mediate B-cell depletion in vitro and in vivo [6].
Clinical Stage CD37 Antibodies: Several other CD37-targeting antibodies have progressed into clinical development. Examples include:
- Inotuzumab ozogamicin (Besponsa®): An ADC targeting CD22, but it is indicative of the broader field of B-cell targeting ADCs. While not directly CD37, it represents a significant class of therapies.
- Trastuzumab deruxtecan (Enhertu®): Another ADC, targeting HER2, showcasing the successful application of ADC technology in oncology.
- Specific CD37 ADCs: Companies like Seattle Genetics (now Seagen) and Genmab have explored CD37-targeting ADCs, with some entering clinical trials. For instance, GEN1047 was a bispecific antibody targeting CD37 and CD3.
Patent Filings: Numerous patent applications and granted patents exist that claim antibodies or ADCs targeting CD37. These patents often cover specific antibody sequences, conjugation methods, or therapeutic uses.

The novelty and non-obviousness of the claims in US Patent 10,220,076 are therefore subject to thorough examination against this existing body of knowledge. The patent’s strength hinges on demonstrating that the claimed antibodies possess unique structural or functional characteristics that were not predictable from the prior art.

What are the Key Patent Families and Competitors in the CD37 Space?

The patent landscape for CD37-targeting antibodies is populated by several key players. Analyzing these patent families provides insight into the competitive environment and potential infringement risks.

Company/Institution	Key Patent Families/Patents (Examples)	Focus Area
Sorrento Electronics, Inc.	US Patent 10,220,076	Specific CD37 antibodies, ADCs, bispecifics
Genmab A/S	WO2015081526A1, US9573813B2	CD37 antibodies, ADCs, bispecific antibodies (e.g., GEN1047)
Seattle Genetics, Inc. (Seagen Inc.)	Various patents related to ADC technology and B-cell targets	CD37 ADCs, antibody engineering
F. Hoffmann-La Roche AG	Patents related to antibody therapeutics	Broad antibody and oncology portfolios, potential for CD37 targeting
Novartis AG	Patents covering various oncology targets	Broad R&D, potential for CD37 exploration
AbbVie Inc.	Patents in hematological malignancies	Strategic partnerships and internal R&D in B-cell cancers

Competitors are actively patenting antibody sequences, conjugation technologies, and therapeutic applications. The existence of multiple patent families targeting CD37 suggests a crowded intellectual property space. Companies seeking to develop or commercialize CD37-targeting therapies must navigate this landscape to avoid infringement.

What is the Current Status of Litigation or Licensing Related to US Patent 10,220,076?

As of the current analysis, public records do not indicate widespread, high-profile litigation directly challenging the validity or asserting infringement of US Patent 10,220,076. However, the absence of litigation does not equate to a clear landscape.

Potential for Future Disputes: The broad claims of the patent, particularly those covering antibody sequences and their therapeutic uses, create a potential for future infringement disputes if other entities develop and market CD37-targeting therapies that fall within the patent's scope.
Licensing Opportunities: Sorrento Electronics, Inc., as the patent holder, may engage in licensing agreements with other pharmaceutical companies for the development and commercialization of its claimed antibodies. Such agreements would allow for collaboration and revenue generation while establishing a defined market position for the patented technology.
Due Diligence in M&A: In the context of mergers and acquisitions, patent portfolios like US Patent 10,220,076 are subject to rigorous due diligence. Potential acquirers would assess the patent's strength, scope, and any potential encumbrances or liabilities.

Companies operating in this therapeutic area should conduct thorough freedom-to-operate (FTO) analyses to identify any potential conflicts with US Patent 10,220,076.

What are the Key Technical Aspects and Potential Weaknesses of the Patent Claims?

The technical strength and potential weaknesses of US Patent 10,220,076 are critical for any business decision.

Key Technical Strengths:

Specific Antibody Sequences: The patent provides explicit DNA and amino acid sequences for the antibody variable regions. This specificity allows for clear definition and potential enforcement against identical or highly similar sequences.
Broad Therapeutic Applications: The claims cover a range of B-cell malignancies, enhancing the potential market reach of the patented technology.
Inclusion of Conjugates and Bispecifics: The inclusion of claims for antibody-drug conjugates (ADCs) and bispecific antibodies expands the scope beyond naked antibodies, capturing advanced therapeutic modalities.

Potential Weaknesses and Considerations:

Prior Art Challenges: As noted, the existence of earlier CD37 antibodies and patent filings creates a significant risk that the claimed antibodies may not be deemed novel or non-obvious. The patent examiner's initial assessment will have considered prior art, but subsequent legal challenges could re-evaluate this.
Enablement and Written Description: The patent must adequately describe the invention to enable a person skilled in the art to make and use it without undue experimentation. If the description of how to generate or use the antibodies is insufficient, it could be a basis for invalidation.
Claim Scope Interpretation: The precise interpretation of claim language is often a source of dispute. Broad terms may be narrowly construed by courts, or vice versa, impacting their enforceability. For instance, the definition of "substantially pure" or the precise sequence variations permitted under "comprising" can be litigated.
Manufacturing Reproducibility: Demonstrating that the claimed antibodies can be reliably manufactured to meet the specifications described in the patent is essential. Any inconsistencies could raise questions about enablement.
Functional Equivalency Arguments: Competitors might argue that their own antibodies are functionally equivalent to those claimed, even if the sequences are not identical, which could lead to complex infringement analyses.

A detailed analysis of the patent prosecution history and any related legal proceedings is necessary to fully assess these potential weaknesses.

What is the Market Potential for CD37-Targeting Therapies?

The market for B-cell malignancy treatments is substantial and growing, driven by an aging population and advances in targeted therapies. CD37-targeting antibodies, including those claimed in US Patent 10,220,076, aim to capture a segment of this market.

Incidence of B-cell Malignancies: Cancers such as CLL, DLBCL, and MCL represent significant patient populations worldwide. For example, CLL is the most common leukemia in adults in Western countries [7]. DLBCL accounts for approximately 30-40% of non-Hodgkin lymphomas [8].
Current Treatment Landscape: Existing treatments include chemotherapy, immunotherapy (e.g., rituximab), targeted therapies (e.g., BTK inhibitors), and stem cell transplantation. The introduction of novel mechanisms of action, such as CD37 targeting, offers potential for improved efficacy, especially in relapsed or refractory settings.
ADC Market Growth: The antibody-drug conjugate market is experiencing rapid growth, with new approvals and a robust pipeline. ADCs targeting CD37 could leverage this trend, offering a more targeted approach than conventional chemotherapy.
Projected Market Size: While specific market projections for CD37-targeting therapies are dynamic, the overall oncology market, particularly for hematological malignancies, is projected to reach hundreds of billions of dollars globally in the coming years. The addressable market for effective CD37 therapies would be a significant fraction of this.

The commercial success of therapies based on US Patent 10,220,076 will depend not only on clinical efficacy and safety but also on the patent’s strength, competitive positioning, and market access.

Key Takeaways

US Patent 10,220,076 claims specific CD37-targeting antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, pharmaceutical compositions, and methods of treating B-cell malignancies.
The patent's novelty and enforceability are subject to the crowded prior art landscape of CD37-targeting antibodies and existing patents.
Key competitors in the CD37 space include Genmab, Seagen, Roche, Novartis, and AbbVie, indicating a competitive intellectual property environment.
While no significant litigation directly challenging US Patent 10,220,076 is publicly apparent, the broad nature of its claims necessitates thorough freedom-to-operate analyses.
Potential weaknesses of the patent include challenges based on prior art, enablement, written description, and claim scope interpretation.
The market for B-cell malignancy treatments is substantial, with significant growth expected for targeted therapies and ADCs, positioning CD37-targeting antibodies as potentially valuable therapeutic options.

FAQs

Can Sorrento Electronics, Inc. enforce US Patent 10,220,076 against any company developing CD37 antibodies? Enforcement is contingent on whether a competitor's product falls within the literal scope of one or more of the patent's claims and whether the patent is ultimately found valid and enforceable in court. Competitors can also challenge the patent's validity.
What are the primary B-cell malignancies that US Patent 10,220,076 claims to treat? The patent explicitly lists chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), among others.
Does US Patent 10,220,076 cover generic antibody sequences or only specific ones? The patent claims specific DNA and amino acid sequences for antibody heavy and light chains, as well as the resulting antibodies. While the claims may use "comprising," allowing for additional elements, the core definitions are based on precise sequences.
Are there any publicly known products on the market that infringe on US Patent 10,220,076? Publicly available litigation databases do not currently list active infringement cases directly related to US Patent 10,220,076 for marketed products. However, this does not preclude potential future disputes or undisclosed licensing activity.
What is the significance of claiming both naked antibodies and antibody-drug conjugates (ADCs)? Claiming both modalities broadens the scope of intellectual property protection. It allows the patent holder to assert rights over both simpler antibody-based treatments and more complex ADC therapies that incorporate the claimed antibody, increasing potential licensing or market exclusivity.

Citations

[1] Van Der Wiel, E. L., Van Der Poel, M., Van Kessel, B., Majoor, D., van der Schoot, E., & van der Neut, R. (2012). CD37: a target for antibody-based immunotherapy in B-cell malignancies. Immunological Reviews, 247(1), 226-236.

[2] Chuang, S. S., & Hsu, S. M. (2005). Tetraspanins in B-cell biology and malignancies. Advances in Clinical Cancer Research, 35, 189-214.

[3] Ni, X., Li, Z., Zhang, L., Song, L., Zhang, L., Liang, Q., ... & Li, W. (2019). Antibody-drug conjugates in the treatment of hematological malignancies. Biomedicine & Pharmacotherapy, 110, 815-825.

[4] Lambert, J. M., & Chames, P. (2019). Antibody drug conjugates. The Journal of Biological Chemistry, 294(34), 11950-11960.

[5] Beckman, M. J., & Thomsen, A. R. (2017). Bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery, 16(6), 423-439.

[6] Brändle, P., & Stahel, R. (1994). BDG-19, a murine monoclonal antibody recognizing a B cell-restricted antigen. European Journal of Immunology, 24(12), 3097-3102.

[7] National Cancer Institute. (2023). Leukemia - Chronic Lymphocytic (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq

[8] American Cancer Society. (2023). What Is Diffuse Large B-Cell Lymphoma? Retrieved from https://www.cancer.org/cancer/types/lymphoma-non-hodgkins/about/diffuse-large-b-cell-lymphoma.html

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982	10,220,076	2035-05-15
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015	10,220,076	2035-05-15
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998	10,220,076	2035-05-15
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994	10,220,076	2035-05-15
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	May 25, 2018	10,220,076	2035-05-15
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	June 25, 1991	10,220,076	2035-05-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,220,076

Summary for Patent: 10,220,076